Roche to buy US gene therapy group Spark for $4.3 bn

Swiss pharmaceuticals giant Roche said Monday it reached a deal worth $4.3 billion (3.7 billion euros) to buy US group Spark Therapeutics, which specialises in the development of gene therapy drugs. Roche said the deal was approved by the boards of both companies, offering $114.50 a share, a premium to…